Aims: Delay of childhood vaccinations is common and influences efforts to reduce targeted diseases. In Denmark, the diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b (DTaP-IPV-Hib) vaccine is recommended at ages 3, 5 and 12 months and the first measles-mumps-rubella vaccine (MMR-1) at 15 months. Following guidelines, children delayed at age 15 months should receive MMR-1 and DTaP-IPV-Hib-3 simultaneously, unless DTaP-IPV-Hib-2 was received less than 6 months ago, when MMR-1 alone is recommended. We studied compliance with these guidelines and the reasons for non-compliance with a focus on vaccination providers. Methods: We used a nationwide register-based cohort study of children born in Denmark between January 2000 and June 2013, who were lacking MMR-1 and DTaP-IPV-Hib-3 at age 15 months and were followed to 24 months. We also performed semi-structured telephone interviews with vaccination providers. Results: The study consisted of 156,921 children (18% of the children born in the period). Among the 40,060 children who had received DTaP-IPV-Hib-2 less than 6 months ago, 37,892 (95%) received MMR-1 alone. Among the 88,469 children who had received DTaP-IPV-Hib-2 more than 6 months ago, 6334 (7%) received DTaP-IPV-Hib-3 and MMR-1 simultaneously. The interviews indicated that some vaccination providers are reluctant to give multiple vaccinations at the same visit and some have a preference of following the usual sequence in the programme. Conclusions: Vaccination providers generally complied with the recommended minimum 6 months' interval between DTaP-IPV-Hib-2 and DTaP-IPV-Hib-3. Conversely, there was a low compliance with the recommendation to administer DTaP-IPV-Hib-3 and MMR-1 simultaneously. More efforts are needed to ensure timely vaccination.
Introduction
The World Health Organization recommends that the vaccination coverage for the live attenuated vaccine against measles, mumps and rubella (MMR) should be 95% [1] . However, this goal has not been reached for any Danish birth cohort and increasing vaccination coverage is a high priority for the Danish health authorities [2, 3] . Delay in vaccinations is common and could influence vaccination coverage and thereby efforts to reduce or eliminate the targeted diseases [4] [5] [6] . There are national guidelines in Denmark that describe how to complete the schedule for children who are delayed in the childhood Vaccination Programme, to minimize delay and increase vaccine coverage [7] .
Vaccines in the childhood Vaccination Programme in Denmark are free of charge. All citizens are assigned to a general medical practice, where childhood vaccinations are administered by the general practitioners (GPs) or their assistants (usually nurses) [8] . The parents are informed about the childhood Vaccination Programme by their GP at the first visit after delivery (scheduled for 5 weeks of age); the parents are responsible for booking the subsequent vaccination appointments. The recommended vaccination schedule for Danish children includes three inactivated vaccine doses against diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b (DTaP-IPV-Hib) at ages 3, 5 and 12 months, and the first dose of MMR (MMR-1) at age 15 months (supplementary Table  s1 , available online) [7] . The guidelines recommend at least 6 months between the second and third DTaP-IPV-Hib dose. If children lack two or more vaccines, the vaccines can be administered simultaneously [7] .
Vaccination providers play a key part in vaccinating children with delayed vaccines according to these guidelines. A knowledge of the compliance with these guidelines and determinants of non-compliance is important for future interventions to increase vaccination coverage. Therefore the aim of this study was to examine compliance with the guidelines for the administration of delayed vaccination and determinants of non-compliance with a focus on the vaccination providers.
Methods
The study was conducted in Denmark. We performed a retrospective nationwide register-based cohort study describing the sequences of DTaP-IPV-Hib-3 and MMR-1 vaccinations in the period from 15 to 24 months of age for Danish children who by age 15 months had received only two doses of DTaP-IPV-Hib and no MMR-1. In this cohort, we also examined whether sex, age, months since DTaP-IPV-Hib-2, vaccination period and province affected the vaccines provided from 15 to 24 months of age. We identified GPs who had vaccinated at least 25 children with delayed childhood vaccinations and eligible for both DTaP-IPV-Hib-3 and MMR-1 (i.e. 6 months had passed since DTaP-IPV-Hib-2) and examined how these GPs would vaccinate delayed children. We conducted qualitative interviews with 12 of these vaccination providers.
The Danish Vaccination Register
Identification codes identify each general practice in Denmark, which can include several GPs and assistants. The GP identification code is used to report vaccines to the Danish national Health service Register for reimbursement and to the national Danish Vaccination Register (DVR) [9, 10] . The DVR became operative in February 2013 and has vaccination entries collected from the Danish national Health service Register dating back to 1996. The purpose of the DVR is to ensure a high quality in monitoring effectiveness, vaccine safety and compliance with vaccination [9] .
Cohort
All children in Denmark are assigned a unique personal identification number at birth, including information about the date of birth and sex of the child. This unique personal identification number is included in the DVR, which enabled us to identify the cohort in the DVR. The cohort included all children born from 1 January 2000 to 30 June 2013 who, by age 15 months, had received only two doses of DTaP-IPV-Hib and no MMR-1. We followed the cohort from 15 to 24 months of age and therefore the last follow-up date was 30 June 2015. Because all available children were included, no power calculation was made.
Data and variables
We obtained information from the DVR about vaccines, vaccination dates, birth date, sex, GP identification code and municipality. Based on the birth date and vaccination date, we calculated the age at the first vaccination visit after age 15 months, equivalent to the child's third vaccination visit, and the time between DTaP-IPV-Hib-2 and the third vaccination visit. There have been some changes in the Danish childhood Vaccination Programme during the study period (supplementary Table s1 , available online). Based on these changes in the vaccination programme, we defined three calendar periods where the third vaccination visit could include two or three injections: from 1 January 2000 to 30 June 2002, the possible vaccines were DTaP-IPV, Hib and MMR; from 1 July 2002 to 30 september 2007, the possible vaccines were DTaP-IPV-Hib and MMR; and from 1 October 2007 to 30 June 2015, the possible vaccines were DTaP-IPV-Hib, pneumococcal conjugate vaccine (PcV) and MMR. The Danish municipalities were allocated to 11 Danish provinces [11] .
Statistical methods
The cohort was divided into two subgroups: children with the third vaccination visit less than 6 months after DTaP-IPV-Hib-2 (<6 months) and children with the third vaccination visit more than 6 months after DTaP-IPV-Hib-2 (6 months+). For each subgroup, we calculated the proportion of children who received either DTaP-IPV-Hib-3, MMR-1 or both vaccines simultaneously by sex, age in months at the third vaccination visit, months since DTaP-IPV-Hib-2, vaccination period and province.
Determinants for vaccination among children in the 6 months+ subgroup were studied using logbinomial regression to obtain adjusted prevalence ratios for receiving the DTaP-IPV-Hib-3 and MMR-1 vaccination simultaneously, as recommended, compared with receiving either vaccine alone. stata version 14 was used for the analyses.
Cohort of GP practices
We identified all GP practices that had at least 25 vaccination visits from children in the 6 months+ subgroup. For each GP practice, we calculated the proportion of children receiving DTaP-IPV-Hib-3 alone, MMR-1 alone or both vaccines simultaneously at the third vaccination visit. These three proportions for each GP practice were plotted in a triplot using sigmaplot 13.0.
Qualitative studies
Based on the cohort of GP practices, we identified practices for semi-structured telephone interviews to identify reasons for non-compliance with the vaccination guidelines for children delayed on DTaP-IPV-Hib-3. We aimed for 12 interviews with three practices, each following the four strategies: high proportion of MMR-1 alone, high proportion of DTaP-IPV-Hib-3 alone, high proportion of DTaP-IPV-Hib-3 and MMR-1 simultaneously, or roughly same proportion of MMR-1 alone and DTaP-IPV-Hib-3 alone. We included practices with only one GP to increase the likelihood that only one person in the practice was responsible for vaccinations. Between March and May 2016, cHs performed the semistructured telephone interviews, which contained both open and closed questions covering three main areas: performance of a regular vaccination visit; vaccination of children delayed on DTaP-IPV-Hib-3; and information on vaccination guidelines. The interview guide was piloted twice on nurses performing childhood vaccinations, resulting in some changes to the interview guide (the final version of the interview guide is provided in the supplementary Material, available online). The pilot interviews were not used in the analysis. Based on the notes from the interviews, ss condensed the information from the interviews and cHs checked the condensation. We regarded that statements such as, 'I would always do …, because …' and 'my main concern is …' indicated issues important to the interviewee.
Ethics and permits
statens serum Institut has access to the DVR to measure vaccination coverage and to conduct studies on vaccine effectiveness and vaccine safety. This study was register-based and enclosed at the following notification to the Danish Data Protection Agency: epidemiological surveillance: jr.nr. 2008-54-0474. Informed oral consent was obtained for the interviews with the vaccination providers.
Results
Among the 855,132 children born in Denmark from January 2000 to June 2013 [12] , 156,921 children (18%) had received only DTaP-IPV-Hib-1 and -2 and no MMR-1 by age 15 months and were therefore included in the cohort under study ( Figure 1 ). By age 24 months among children in the included cohort, 41,402 (26%) had received both MMR-1 and DTaP-IPV-Hib-3, either simultaneously or at two separate visits; 18,396 (12%) children had received only DTaP-IPV-Hib-3; 68,731 (44%) had received only MMR-1; and 28,392 (18%) received neither MMR-1 nor DTaP-IPV-Hib-3 before 24 months.
Among the 40,060 children in the <6 months subgroup, 37,892 (95%) received MMR-1 as recommended ( Figure 1 ). Of the 88,469 children in the 6 months+ subgroup, only 6334 (7%) received MMR-1 and DTaP-IPV-Hib-3 simultaneously as recommended ( Figure 1 ).
Vaccination determinants
In the 6 months+ subgroup, sex, age, months since DTaP-IPV-Hib-2, vaccination period and province were associated with compliance with the vaccination guidelines (Table I) .
In the <6 months subgroup, the median age when vaccinated was 5 months for DTaP-IPV-Hib-1; 12 months for DTaP-IPV-Hib-2; and 16 months for either DTaP-IPV-Hib-3, MMR-1, or both administered simultaneously (supplementary Figure s1A , available online).
In the 6 months+ subgroup, the median age when vaccinated was about 3 months for DTaP-IPV-Hib-1; 5 months for DTaP-IPV-Hib-2; and 16 months for either DTaP-IPV-Hib-3, MMR-1, or both simultaneously (supplementary Figure s1B , available online). There Figure 1 . Overview of the children included in this study and their vaccination patterns from 15 months to 24 months of age. note: Percentage is calculated from the number in the previous box. DTaP-IPV-Hib: inactivated vaccine against diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b (the number following this abbreviation indicate dose number); MMR-1: the first dose of the live attenuated vaccine against measles, mumps and rubella; <6 months: less than 6 months since receiving DTaP-IPV-Hib-2 at the third vaccination visit; 6 months+: 6 months or more since receiving DTaP-IPV-Hib-2 at the third vaccination visit; N: number of children.
was a larger variation in the 6 months+ group than in the <6 months subgroup (supplementary Figure s1 , available online).
Vaccination distribution per GP practice
We identified 1661 (56%) of 2965 GP practices with at least 25 vaccination visits from children in the 6 months+ subgroup. Most of these GP practices had a low proportion of children receiving MMR-1 and DTaP-IPV-Hib-3 simultaneously ( Figure 2) ; 526 (31.7%) never administered MMR-1 and DTaP-IPV-Hib-3 simultaneously. All GP practices had administered both MMR-1 alone or DTaP-IPV-Hib-3 alone ( Figure 2 ); some GP practices had a greater proportion of children administered MMR-1 alone and some GP practices had a greater proportion of children administered DTaP-IPV-Hib-3 alone.
Semi-structured telephone interviews
We performed 12 semi-structured telephone interviews with vaccination providers following the selection criteria given in supplementary Figure s2 (available online). All informants reported that no child was vaccinated before inspection of the vaccination card or medical record.
In most practices, the minimum interval between DTaP-IPV-Hib-2 and 3 was respected, but the choice of vaccine and arguments for the choices differed. Table II contains all the arguments mentioned for different vaccine choices. The main argument for providing vaccines simultaneously was to achieve full protection. The main reason for choosing DTaP-IPV-Hib-3 alone was to follow the normal vaccination sequence, whereas the most important reasons for choosing MMR-1 were reluctance towards administering more than two vaccines at the same visit and that the child was already partially immune towards diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b after two DTaP-IPV-Hib vaccines.
none of the 12 informants stated that the choice of vaccine was influenced by the child's current health condition (colds, febrile disease), preterm birth or chronic disease, except for one informant who mentioned that immunosuppressed children should not be vaccinated with MMR-1.
Most informants had occasionally experienced parental concern in relation to DTaP-IPV-Hib and MMR-1 vaccines, but all emphasized that it was an infrequent occurrence. none of the informants had any concern regarding any of the vaccines. The results regarding the considerations of the vaccination providers about the information available on vaccination guidelines are given in the supplementary Material (available online).
Discussion
When Danish children lacking DTaP-IPV-Hib-3 and MMR-1 at age 15 months were vaccinated less than 6 months after DTaP-IPV-Hib-2, they were mainly vaccinated with MMR-1 alone, as recommended (95%). Only 2% of these children received DTaP-IPV-Hib-3 at a later visit. children vaccinated 6 months or more after DTaP-IPV-Hib-2 were rarely vaccinated, as recommended, with DTaP-IPV-Hib-3 and MMR-1 simultaneously. These children usually received DTaP-IPV-Hib-3 alone (54%), but MMR-1 alone was also frequently given (39%). The interviews with the vaccination providers indicated that reluctance to give three injections at one visit could give a preference for either DTaP-IPV-Hib-3 alone or MMR-1 alone; a preference for keeping the vaccination sequence could result in the administration of DTaP-IPV-Hib-3 alone.
Strengths and weaknesses
We used vaccination information from the DVR, which was based on the Danish national Health service Register with vaccination information provided for reimbursement purposes [10] . The GPs therefore have an economic incentive to report vaccinations. However, previous studies have found underreporting of MMR-1 [13] and DTaP-IPV revaccination scheduled at age 5 years [14] . underreporting probably occurs for all vaccines. Thus if the registration of DTaP-IPV-Hib-3 before age 15 months is missing, too many children could be included in our cohort. Provided the parent and their GP had correct information on their vaccination status, these children would fall into the category of MMR-1 alone in our study, inflating this group. However, based on the numbers, even with considerable underreporting of DTaP-IPV-Hib-3 before age 15 months, there would still be a large group left who only received MMR-1, even though they had been eligible for MMR-1 and DTaP-IPV-Hib-3. children with immune defects or other absolute contraindications to MMR-1 vaccination were present in this study if they fulfilled the inclusion criteria and would have led to a larger preference for DTaP-IPV-Hib. nevertheless, such immune defects are rare and would not influence the proportions to any large extent.
We did not have information about changes in vaccination provider or the number of vaccination providers within each practice. Thus we cannot determine whether the fact that no GP practice seemed to make the same choice every time reflects one vaccination provider making different choices on different occasions, or more vaccination providers within a practice who had different vaccination choices. For the interviews, we aimed at including GP practices with different vaccination strategies, but the same limitations could apply. Figure 2 . Triplot of the proportion of vaccination visits resulting in administration of DTaP-IPV-Hib-3 and MMR-1 simultaneously, DTaP-IPV-Hib-3 alone or MMR-1 alone for children with 6 months or more since DTaP-IPV-Hib2 at the third vaccination visit for each GP practice. note: The plot is based on data from 1661 GP practices that had at least 25 different children having a vaccination visit more than 6 months after DTaP-IPV-Hib-2. each cross in the plot represent one GP practice. The cross is placed on the coordinate that represents the joint distribution of the proportion of children vaccinated with DTaP-IPV-Hib-3 and MMR-1 simultaneously, the proportion of children vaccinated with DTaP-IPV-Hib-3 alone and the proportion of children vaccinated with MMR-1 alone for each GP practice. The reading direction for the distribution of the vaccine choice is indicated by the arrows and the gridlines, e.g. a cross in the top apex indicates that 100% of the children vaccinated by the GP practice had received DTaP-IPV-Hib-3 and MMR-1 simultaneously, 0% had received DTaP-IPV-Hib-3 alone and 0% MMR-1 alone. DTaP-IPV-Hib-3: Inactivated vaccine against diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b; MMR-1: live attenuated vaccine against measles, mumps and rubella; GP: general practitioner.
The vaccination programmes differ between countries and the findings from the current study might not be directly comparable with other settings.
Health consequences of delayed vaccinations
With respect to the specific disease-protective effects of the vaccines, children who are not vaccinated timely have a greater risk of contracting pertussis and measles when there is an epidemic [15, 16] . In addition to their specific effects, vaccines may have important non-specific effects [17] [18] [19] . A Danish study found that MMR-1 compared with DTaP-IPV-Hib-3 as the most recent vaccination was associated with a lower rate of admission for any type of infection [20] . The numbers were small, but indicated that if DTaP-IPV-Hib-3 was administered with or after MMR-1, the same beneficial non-specific effect was not seen [20, 21] . This supports the importance of receiving the vaccines at the recommended age and in the recommended schedule.
Timely vaccinations and vaccination coverage
The current study included children who had received DTaP-IPV-Hib-2 before age 15 months. Thus we do not know how many children received no or only one dose of DTaP-IPV-Hib before age 15 months. However, the number of children included in the study indicates that at least 18% of Danish children have not received DTaP-IPV-Hib-3 by age 15 months and only 26% of these children are fully vaccinated by age 2 years. studies from norway, Belgium and the usA shows similar challenges with timely vaccinations [5, 22, 23] . Table II. condensation of arguments for different vaccination choices for children who were lacking both DTaP-IPV-Hib-3 and MMR-1 Table includes all the arguments mentioned by at least one vaccination provider during the interviews. Often one provider used more arguments to arrive at a decision. One provider could choose DTaP-IPV-Hib-3 if he/she found it most important to follow the sequence of vaccines in the ordinary programme. Another provider could choose MMR-1 if he/she found it most important the provide immunity towards measles, mumps and rubella compared with providing a modest additional immunity towards diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b because the children already were partially immune towards these diseases as a result of the two previous DTaP-IPV-Hib vaccinations. Though the providers might have a preferred choice, this could be altered or further enforced by special circumstances, e.g. current epidemics of the vaccine-targeted diseases could influence the choice, as could children's forthcoming travels abroad, parental preferences, or lacking child cooperation during vaccination sessions.
One possibility for improving vaccination coverage is to ensure that children lacking vaccines are vaccinated with all lacking vaccines at the first vaccination opportunity. We found that this rarely occurs when both DTaP-IPV-Hib-3 and MMR-1 are lacking for Danish children. This is in line with findings from other studies of the occurrence of missed vaccination opportunities [24, 25] . To overcome this non-compliance, this study indicates that it is important to address vaccination providers' reluctance to give three injections at the same visit and their priority of following the sequence of vaccines.
A few of the informants said that parental preference for only one vaccine at a time could also make them deviate from the guidelines. The parents' wishes regarding the vaccination of their child should be respected. However, information about the vaccines can be communicated to the parents in many ways and perhaps an approach that is not only based on evidence and statistics, but a narrative communication of the nature of vaccine-preventable diseases and how they affected children and families before the vaccination era [26] . some informants placed 'lack of child cooperation' as a reason why they did not administer MMR-1 and DTaP-IPV-Hib-3 simultaneously. Pain, anxiety and stress are crucial factors regarding children's cooperation and several things can ensure optimum cooperation. A review from 2009 provides advice that could easily be implemented in daily routines: upright positioning of the child, stroking the skin close to the vaccination before and during vaccination and, most importantly in relation to our study, when multiple vaccines are injected sequentially, choosing the least painful vaccine first [27] . Other studies have shown some beneficial effect of topical anaesthetics [28, 29] .
Increasing the vaccination coverage is a high priority for the Danish health authorities and in May 2014 a programme was initiated where written reminders are sent to parents of children aged 2, 6.5 and 14 years, who were lacking any of the vaccines recommended for the specific ages. The primary analysis of this initiative indicates a positive effect on vaccination coverage [3] . However, that programme focuses only on catching up. Our study indicates that some of the children might be delayed earlier on, as indicated by the median age of DTaP-IPV-Hib-1 and DTaP-IPV-Hib-2. The information to the parents regarding timely vaccinations may not be clear enough and perhaps further proactive initiatives should be considered. The DVR provides a unique platform with information on all given vaccines that could be used for generating electronic reminders by mail and/or sMs before scheduled vaccination dates [30, 31] . These could be supplemented by follow-up reminders in case of delay. By improving the timeliness of DTaP-IPV-Hib-1-3, all children would end up having MMR-1 only as their most recent vaccination and this may be associated with additional health benefits [20, 21] .
Conclusions
This study showed high compliance with the guidelines regarding the minimum intervals between DTaP-IPV-Hib-2 and DTaP-IPV-Hib-3 among Danish vaccination providers. However, there was a low compliance regarding the simultaneous administration of DTaP-IPV-Hib-3 and MMR-1 if 6 months or more had passed since vaccination with DTaP-IPV-Hib-2. The qualitative interviews suggested that contributing factors could be vaccination providers' reluctance towards providing multiple injections and a preference for following the vaccination sequence in the vaccination programme. Further efforts are needed to improve the timeliness and coverage of vaccines in the Danish childhood Vaccination Programme.
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